IMPEDIMED LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.08 AUD | +1.27% |
|
0.00% | -44.83% |
| Apr. 30 | ImpediMed's Qaurterly Revenue Rises in Fiscal Q3; Shares Fall 8% | MT |
| Apr. 30 | Transcript : ImpediMed Limited, Q3 2024 Earnings Call, Apr 30, 2024 |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 10.85M 7.17M | Sales 2025 * | 19.15M 12.65M | Capitalization | 160M 106M |
|---|---|---|---|---|---|
| Net income 2024 * | -21M -13.88M | Net income 2025 * | -14M -9.25M | EV / Sales 2024 * | 12.5 x |
| Net cash position 2024 * | 24.42M 16.13M | Net cash position 2025 * | 13.15M 8.69M | EV / Sales 2025 * | 7.66 x |
| P/E ratio 2024 * |
-7.99
x | P/E ratio 2025 * |
-12.4
x | Employees | 76 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.74% |
More Fundamentals
* Assessed data
More news
Latest transcript on ImpediMed Limited
| 1 day | +1.27% | ||
| Current month | -4.76% | ||
| 1 month | -10.11% | ||
| 3 months | -3.61% | ||
| 6 months | -40.74% | ||
| Current year | -44.83% |
1 week
0.08
0.08
1 month
0.080.11
Current year
0.080.16
1 year
0.080.24
3 years
0.050.24
5 years
0.030.24
10 years
0.031.82
| Managers | Title | Age | Since |
|---|---|---|---|
Parmjot Bains
CEO | Chief Executive Officer | - | Jan. 07 |
McGregor Grant
DFI | Director of Finance/CFO | - | 23-09-27 |
Steven Chen
CTO | Chief Tech/Sci/R&D Officer | - | 23-09-25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Parmjot Bains
CEO | Chief Executive Officer | - | Jan. 07 |
McGregor Grant
DFI | Director of Finance/CFO | - | 23-09-27 |
| Chairman | - | 23-09-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 0.08 | +1.27% | 834 952 |
| 24-05-13 | 0.079 | 0.00% | 2,062,053 |
| 24-05-10 | 0.079 | +1.28% | 2,344,234 |
| 24-05-09 | 0.078 | 0.00% | 1,571,317 |
| 24-05-08 | 0.078 | -2.50% | 700,212 |
Delayed Quote Australian S.E., May 14, 2024 at 02:10 am EDT
More quotes
ImpediMed Limited is an Australia-based medical software technology company. The Company is engaged in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services with a focus on the early detection of lymphoedema and heart failure. It measures, monitors and manages fluid status and tissue composition using BIS. The Companyâs SOZO digital health platform uses BIS technology to measure and track critical information about the human body to aid clinicians in managing chronic disease and maximizing patient health. Its SFB7 measures fluid status and tissue composition for clinical and research applications. It offers ImpediVET, a single-channel, tetrapolar BIS device that measures fluid status and tissue composition for veterinary applications from laboratory research to clinic. SOZO applications include L-Dex Analysis for Lymphedema, BodyComp Analysis, Segmental BodyComp analysis, and HF-Dex analysis for heart failure.
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.079
AUD
Average target price
0.1753
AUD
Spread / Average Target
+121.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -44.83% | 106M | |
| +11.29% | 225B | |
| +8.76% | 186B | |
| +12.90% | 135B | |
| +25.95% | 107B | |
| +0.19% | 63.56B | |
| +11.08% | 51.04B | |
| +5.62% | 51.32B | |
| +6.28% | 43.3B | |
| +4.80% | 36.99B |
- Stock Market
- Equities
- IPD Stock
